Blue Jay Capital Management
Latest statistics and disclosures from Blue Jay Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Tesaro, Clovis Oncology, INCY, IRWD, Wright Medical Group Nv, and represent 30.98% of Blue Jay Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Qiagen Nv (+$7.3M), SNN (+$7.0M), Portola Pharmaceuticals (+$6.7M), NBIX (+$6.7M), BKD (+$6.6M), ICLR (+$6.2M), ALGN (+$5.1M), ILMN, ISRG, Wright Medical Group Nv.
- Started 9 new stock positions in SNN, ALGN, ISRG, Portola Pharmaceuticals, Qiagen Nv, NBIX, ILMN, ICLR, BKD.
- Reduced shares in these 10 stocks: , GMED (-$12M), , BMY (-$11M), C.R. Bard (-$9.3M), NuVasive (-$9.2M), Celgene Corporation (-$9.1M), , Akorn (-$7.2M), Dermira (-$7.2M).
- Sold out of its positions in Akorn, MDRX, C.R. Bard, BIIB, BMY, Celgene Corporation, Dermira, GMED, NuVasive, Qiagen.
- Blue Jay Capital Management was a net seller of stock by $-64M.
- Blue Jay Capital Management has $147M in assets under management (AUM), dropping by -27.85%.
- Central Index Key (CIK): 0001586444
Portfolio Holdings for Blue Jay Capital Management
Blue Jay Capital Management holds 20 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tesaro | 6.4 | $9.4M | -20% | 68k | 139.86 |
|
| Clovis Oncology | 6.3 | $9.3M | -33% | 99k | 93.63 |
|
| Incyte Corporation (INCY) | 6.2 | $9.1M | +3% | 72k | 125.91 |
|
| Ironwood Pharmaceuticals (IRWD) | 6.0 | $8.9M | -30% | 470k | 18.88 |
|
| Wright Medical Group Nv | 6.0 | $8.8M | +4% | 320k | 27.49 |
|
| BioMarin Pharmaceutical (BMRN) | 5.8 | $8.6M | -10% | 95k | 90.82 |
|
| Pra Health Sciences | 5.5 | $8.0M | -23% | 107k | 75.01 |
|
| Edwards Lifesciences (EW) | 5.4 | $8.0M | -25% | 67k | 118.25 |
|
| Abiomed | 5.4 | $7.9M | -26% | 55k | 143.30 |
|
| Nevro (NVRO) | 5.3 | $7.8M | +5% | 105k | 74.43 |
|
| Qiagen Nv | 5.0 | $7.3M | NEW | 218k | 33.53 |
|
| Smith & Nephew (SNN) | 4.8 | $7.0M | NEW | 200k | 34.85 |
|
| Portola Pharmaceuticals | 4.6 | $6.7M | NEW | 120k | 56.17 |
|
| Neurocrine Biosciences (NBIX) | 4.5 | $6.7M | NEW | 145k | 46.00 |
|
| Brookdale Senior Living (BKD) | 4.5 | $6.6M | NEW | 450k | 14.71 |
|
| Icon (ICLR) | 4.2 | $6.2M | NEW | 63k | 97.79 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 4.1 | $6.0M | -42% | 46k | 128.87 |
|
| Align Technology (ALGN) | 3.5 | $5.1M | NEW | 34k | 150.13 |
|
| Illumina (ILMN) | 3.2 | $4.8M | NEW | 28k | 173.53 |
|
| Intuitive Surgical (ISRG) | 3.2 | $4.7M | NEW | 5.0k | 935.40 |
|
Past Filings by Blue Jay Capital Management
SEC 13F filings are viewable for Blue Jay Capital Management going back to 2014
- Blue Jay Capital Management 2017 Q2 filed Aug. 11, 2017
- Blue Jay Capital Management 2017 Q1 filed May 12, 2017
- Blue Jay Capital Management 2016 Q4 filed Feb. 13, 2017
- Blue Jay Capital Management 2016 Q3 filed Nov. 10, 2016
- Blue Jay Capital Management 2016 Q2 filed Aug. 12, 2016
- Blue Jay Capital Management 2016 Q1 filed May 13, 2016
- Blue Jay Capital Management 2015 Q4 filed Feb. 12, 2016
- Blue Jay Capital Management 2015 Q3 filed Nov. 13, 2015
- Blue Jay Capital Management 2015 Q2 filed Aug. 13, 2015
- Blue Jay Capital Management 2015 Q1 filed May 13, 2015
- Blue Jay Capital Management 2014 Q4 filed Feb. 13, 2015